Medtronic rebuffed Senate Finance Committee charges that the company ghostwrote or influenced journal articles about its InFuse bone-growth product while conspiring to paper over adverse events from the treatment.
*Group discounts available on request
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.